3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Breast Neoplasms
4
Prostatic Neoplasms
3
Neoplasm Metastasis
2
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Solid Tumour
1
Recurrence
1
Ovarian Neoplasms
1
Non-small Cell Lung Cancer Metastatic
1
Lymphoma, Mantle-Cell
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma, B-Cell
1
Lung Neoplasms
1
Hereditary Sensory and Autonomic Neuropathies
1
Hematologic Neoplasms
1
Healthy Volunteers (Intended Indication: Metastatic Patients With Triple Negative or HR+ Breast Cancer, or Hormone Sensitive Prostate Cancer)
1
Healthy Participants
1
Endometrial Neoplasms
1
Carcinoma, Squamous Cell
1
Carcinoma, Non-Small-Cell Lung
1
Advanced Solid Tumours
1
Advanced Solid Malignancy,
1
Advanced Solid Malignancy
1
Advanced Gastric Cancer
1
Advanced Cancer
1
Adenocarcinoma
1
Interventions
Nivolumab
13
Surveys and Questionnaires
6
Ipilimumab
6
linrodostat
5
Standard of Care
5
Paclitaxel
5
Bevacizumab
5
Sirolimus
4
Pemetrexed
4
Interviews as Topic
4
Gemcitabine
4
Docetaxel
4
ARRY-334543
4
temsirolimus
3
relatlimab
3
Erlotinib Hydrochloride
3
Cetuximab
3
Carboplatin
3
regorafenib
2
anlotinib
2
abemaciclib
2
Vorinostat
2
Trastuzumab
2
Sorafenib
2
N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide
2
Magnetic Resonance Spectroscopy
2
Doxorubicin
2
Dasatinib
2
Cyclophosphamide
2
vorolanib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Advanced Cancer
×
capivasertib
×
Clear all
NCT02338622
2024-09-26
ComPAKT
Royal Marsden NHS Foundation Trust
Phase 1
Completed
60 enrolled